Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma

BMC Cancer

Zhen Liu¹  Lixia Li³  Zhixiong Yang³  Weiren Luo³  Xin Li¹  Huiling Yang²  Kaitai Yao¹  Bin Wu³  Weiyi Fang¹ 

[1] Cancer Research Institute, Key Lab for Transcriptomics and Proteomics of Human Fatal Diseases Supported by Ministry of Education and Guangdong Province, Southern Medical University, 510515,Guangzhou, PR China

[2] Institute of Clinical Medicine, First Affiliated Hospital of University of South China, 421001, Hengyang, PR China

[3] Department of Respiratory Medicine and Cancer Center, Affiliated Hospital of Guangdong Medical College, 524000, Zhanjiang, PR China

Others  :  1081561
DOI  :  10.1186/1471-2407-10-270

 received in 2009-11-01, accepted in 2010-06-09,  发布年份 2010

【 摘 要 】

Introduction

The aim of the present study was to analyze the expression of matrix metalloproteinase 9 (MMP9) in nasopharyngeal carcinoma (NPC) and its correlation with clinicopathologic features, including the survival of patients with NPC.

Methods

Using real-time PCR, we detected the mRNA expression of MMP9 in normal nasopharyngeal tissues and nasopharyngeal carcinoma (NPC) tissues. Using immunohistochemistry analysis, we analyzed MMP9 protein expression in clinicopathologically characterized 164 NPC cases (116 male and 48 female) with age ranging from 17 to 80 years (median = 48.4 years) and 32 normal nasopharyngeal tissues. Cases with greater than or equal to 6 and less than 6 of the score value of cytoplasmic MMP9 immunostaining were regarded as high expression and low expression, respectively. The relationship between the expression levels of MMP9 and clinical features was analyzed.

Results

The expression level of MMP9 mRNA was markedly greater in NPC tissues than that in the nasopharyngeal tissues. Immunohistochemical analysis revealed that the protein expression of MMP9 detected in NPC tissues was higher than that in the nasopharyngeal tissues (P = 0.004). In addition, high levels of MMP9 protein were positively correlated with the status of lymph node metastasis (N classification) (P = 0.002) and clinical stage (P < 0.001) of NPC patients. Patients with higher MMP9 expression had a significantly shorter overall survival time than did patients with low MMP9 expression. Multivariate analysis suggested that the level of MMP9 expression was an independent prognostic indicator (P = 0.008) for the survival of patients with NPC.

Conclusion

High level of MMP9 expression is a potential unfavorable prognostic factor for patients with NPC.

【 授权许可】

   
2010 Liu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Cho WC: Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007, 6:1. BioMed Central Full Text
• [2]Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, Liu Q, Liu T, Huang J, et al.: Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med 2008, 6:32. BioMed Central Full Text
• [3]Fridman R, Toth M, Pena D, Mobashery S: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995, 55(12):2548-2555.
• [4]Backstrom JR, Tokes ZA: The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem 1995, 64(3):1312-1318.
• [5]Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu TF, Xie WB, Yao KT: Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med 2008, 6:55. BioMed Central Full Text
• [6]Wang S, Zhou J, Wang XY, Hao JM, Chen JZ, Zhang XM, Jin H, Liu L, Zhang YF, Liu J, et al.: Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol 2009, 219(1):114-122.
• [7]Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000, 6(10):4064-4068.
• [8]Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M: Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000, 89(4):715-723.
• [9]Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL, Yuen AP: Clinicopathologic significance of plasma matrix metalloproteinase-2 and -9 levels in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol 2004, 30(5):560-564.
• [10]Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S: Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev 2003, 22(2-3):153-166.
• [11]Loesch M, Zhi HY, Hou SW, Qi XM, Li RS, Basir Z, Iftner T, Cuenda A, Chen G: p38{gamma} MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J Biol Chem 2010, in press.
• [12]Lin LF, Chuang CH, Li CF, Liao CC, Cheng CP, Cheng TL, Shen MR, Tseng JT, Chang WC, Lee WH, Wang JM, et al.: ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer. Cancer Res 2010, 70(1):192-201.
• [13]Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, Collan Y, Pyrhönen S: MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest 2010, 28(1):38-43.
• [14]Zhao ZS, Wang YY, Ye ZY, Tao HQ: Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol Oncol Res 2009, 15(4):589-596.
• [15]Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, Han JX: Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008, 8:241. BioMed Central Full Text
• [16]Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis E, Nonni A, Papassotiriou I, Zografos G: Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 2009, 9:390. BioMed Central Full Text
• [17]Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS: Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 2007, 29(6):564-572.
• [18]Sakata K, Someya M, Omatsu M, Asanuma H, Hasegawa T, Ichimiya S, Hareyama M, Himi T: The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma. BMC Cancer 2007, 7:229. BioMed Central Full Text
• [19]Friedberg MH, Glantz MJ, Klempner MS, Cole BF, Perides G: Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 1998, 82(5):923-930.
• [20]Yoshizaki T, Sato H, Furukawa M, Pagano JS: The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci USA 1998, 95(7):3621-3626.
• [21]Sillanpaa S, Anttila M, Voutilainen K, Ropponen K, Turpeenniemi-Hujanen T, Puistola U, Tammi R, Tammi M, Sironen R, Saarikoski S, Kosma VM: Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol 2007, 104(2):296-303.
• [22]Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004, 10(2):7621-7628.
• [23]Sienel W, Hellers J, Morresi-Hauf A, Lichtinghagen R, Mutschler W, Jochum M, Klein C, Passlick B, Pantel K: Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003, 103(5):647-651.
• [24]Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S: Cancer Invest.MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest 2010, 28(1):38-43.
• [25]Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, Okazawa T, Yanai H, Okita K: Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 2003, 89(11):2116-2121.
• [26]Li Z, Bian LJ, Li Y, Liang YJ, Liang HZ: Expression of protease-activated receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: correlation with clinicopathological features and prognosis. Pathol Res Pract 2009, 205(8):542-550.